Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2025-10-26 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
上海天璇律师事务所关于四川梓橦宫药业股份有限公司2025年第三次临时股东会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the procedural legality of a company's 2025 third extraordinary shareholders meeting. It details the convening, attendance, voting procedures, and results of the shareholders meeting, confirming compliance with relevant laws and company bylaws. It does not contain financial statements, earnings data, or management discussion of financial results. It is not a report of voting results alone but a legal opinion on the meeting's procedural validity. Given the nature of the document as a legal opinion on a shareholders meeting, it fits best under Regulatory Filings (RNS) as it is a compliance/legal document rather than a direct report of voting results or a management report.
2025-10-26 Chinese
关于使用自有闲置资金委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds to purchase financial products. It includes specifics about the amounts, types of financial products, expected yields, investment directions, and risk controls. The document is a disclosure about the company's financing activities related to entrusted wealth management products, including approvals by the board and shareholders, risk management, and detailed tables of current and matured financial products. There is no indication that this is a full financial report, audit report, or earnings release. It is not a regulatory certification or a simple announcement of a report publication. The content fits best with a Capital/Financing Update (CAP) as it relates to the company's capital management and financing activities through entrusted financial products.
2025-10-12 Chinese
关于取得9项实用新型专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of 9 utility model patent certificates by Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the patent types, names, numbers, and the positive impact on the company. There is no financial data, no mention of financial results, no regulatory filings, no voting results, no management changes, no earnings, no capital updates, or any other financial or governance report. The document is a formal announcement about intellectual property achievements, which does not fit into any financial or regulatory report categories. It is a general regulatory announcement about company patents, best classified under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2025-10-12 Chinese
关于收到10个药品再注册批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the receipt of 10 drug re-registration approval notices issued by the Sichuan Provincial Drug Administration. It lists the drugs, their specifications, approval numbers, and validity periods. The document emphasizes the positive impact on the company's production qualifications and includes a risk warning to investors. There is no financial data, no mention of financial results, no management discussion, no voting results, no share transactions, no legal proceedings, and no regulatory certifications. The document is a regulatory announcement about approvals related to product registrations, which does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-10-12 Chinese
关于使用自有闲置资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the use of its own idle funds for cash management by investing in low-risk short-term financial products. It details the purpose, amount, methods, decision-making process, risk analysis, and impact on the company. The document is a formal announcement of a financing or capital management activity, specifically about the company's use of idle funds for investment purposes. It is not a full financial report, audit, or earnings release, nor is it a regulatory filing or voting result. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage.
2025-10-08 Chinese
第四届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 15th meeting of the 4th Board of Directors of Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and mentions that some proposals will be submitted to the shareholders' meeting. The content focuses on board meeting decisions, including the use of idle funds, reappointment of the audit firm, and scheduling a shareholders' meeting. There is no financial data or detailed report content, only the announcement of board resolutions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document length is short (1740 characters), and it is not a full report or financial statement. Therefore, the correct classification is MANG with high confidence.
2025-10-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.